- Home
- CCC vs KNSA Comparison
CCC vs KNSA Comparison
Compare CCC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCC | KNSA |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United Kingdom |
| Employees | 2185 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CCC | KNSA |
|---|---|---|
| Price | $4.95 | $46.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $9.44 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 9.2M | 565.9K |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $10.22 | $38.01 |
| Revenue Next Year | $8.58 | $17.42 |
| P/E Ratio | ★ N/A | $63.27 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $4.81 | $19.42 |
| 52 Week High | $8.68 | $50.03 |
Technical Indicators
Market Signals| Indicator | CCC | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 29.23 | 51.17 |
| Support Level | $4.81 | $39.96 |
| Resistance Level | $6.40 | $48.14 |
| Average True Range (ATR) | 0.29 | 1.83 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 3.50 | 45.20 |
Price Performance
Historical ComparisonAbout CCC CCC Intelligent Solutions Holdings Inc.
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies, and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, AI-enabled digital workflows. It operates in a single segment being Domestic segment, which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in the United States and China. The majority of the revenue is generated from the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.